Lilly unveils first clinical data behind $2.3B Ajax deal, showing JAK inhibitor works ‘right out of the gate’

Key Points:

• Eli Lilly’s acquisition of Ajax Therapeutics, valued up to $2.3 billion, is validated by promising early clinical data showing its Type II JAK2 inhibitor AJ1-11095 significantly reduces spleen volume and symptoms in myelofibrosis patients previously treated with Type I JAK inhibitors.
• In a phase 1 trial, 70% of patients achieved at least a 35% reduction in spleen volume (SVR35), outperforming historical response rates of 0-32% in similar populations, with favorable safety and reductions in mutant JAK2 allele burden.
• The data challenge Incyte’s dominance in the myelofibrosis market, as Lilly’s AJ1-11095 demonstrates broader mutation coverage and higher efficacy compared to Incyte’s CALR-targeted candidate INCA033989, which showed lower response rates in comparable studies.
• Lilly plans to advance AJ1-11095 into phase 3 trials for second-line myelofibrosis and explore additional indications, while maintaining a dual business development strategy that balances early-stage investments with acquisitions of more mature, de-risked assets like Ajax.
• The company emphasizes financial discipline despite its increased capital availability from successful obesity and diabetes products, aiming to optimize pipeline reinvention through strategic, data-backed acquisitions without overpaying.